Company intelligence / Profile preview

Valinor Pharma

Chicago, Illinois, United Statesvalinorrx.com ↗

Ownership: Private
Development stage: Commercial

Overview

Valinor Pharma focused on commercializing therapeutically differentiated products, notably MOVANTIK® (naloxegol), an FDA-approved treatment for opioid-induced constipation. The company achieved significant revenue growth prior to its acquisition by Grünenthal Group in July 2024. MOVANTIK® was already approved and marketed in the United States at the time of acquisition.

Therapeutic areas: Gastroenterology
Modalities: Small molecules (notably naloxegol)
Industry: Biotech

Drug pipeline

1 asset

naloxegol

Commercial

Indications: Opioid-induced constipation

Beyond the preview

Go deeper on Valinor Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Valinor Pharma.

Explore the full profile